Barclays’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-129,600
| Closed | -$10.3M | – | 5237 |
|
|
2025
Q4 | $10.3M | Sell |
129,600
-25,000
| -16% | -$1.88M | ﹤0.01% | 1658 |
|
|
2025
Q3 | $10.1M | Buy |
154,600
+144,000
| +1,358% | +$7.03M | ﹤0.01% | 1654 |
|
|
2025
Q2 | $419K | Hold |
10,600
| – | – | ﹤0.01% | 3858 |
|
|
2025
Q1 | $320K | Buy |
+10,600
| New | +$347K | ﹤0.01% | 3791 |
|
|
2024
Q3 | – | Sell |
-50,000
| Closed | -$2.38M | – | 5374 |
|
|
2024
Q2 | $2.38M | Sell |
50,000
-85,000
| -63% | -$3.49M | ﹤0.01% | 2015 |
|
|
2024
Q1 | $5.85M | Buy |
135,000
+80,000
| +145% | +$3.81M | ﹤0.01% | 1746 |
|
|
2023
Q4 | $2.78M | Sell |
55,000
-5,000
| -8% | -$239K | ﹤0.01% | 2640 |
|
|
2023
Q3 | $2.72M | Buy |
+60,000
| New | +$2.48M | ﹤0.01% | 1704 |
|
|
2021
Q1 | – | Sell |
-41,900
| Closed | -$2.37M | – | 4940 |
|
|
2020
Q4 | $2.37M | Hold |
41,900
| – | – | ﹤0.01% | 2105 |
|
|
2020
Q3 | $1.99M | Sell |
41,900
-1,900
| -4% | -$106K | ﹤0.01% | 2109 |
|
|
2020
Q2 | $2.58M | Sell |
43,800
-9,000
| -17% | -$501K | ﹤0.01% | 1876 |
|
|
2020
Q1 | $2.5M | Sell |
52,800
-19,200
| -27% | -$1.07M | ﹤0.01% | 2078 |
|
|
2019
Q4 | $4.35M | Buy |
72,000
+14,700
| +26% | +$876K | ﹤0.01% | 2154 |
|
|
2019
Q3 | $3.43M | Sell |
57,300
-3,900
| -6% | -$254K | ﹤0.01% | 2240 |
|
|
2019
Q2 | $3.93M | Sell |
61,200
-14,900
| -20% | -$1.05M | ﹤0.01% | 2097 |
|
|
2019
Q1 | $6.18M | Sell |
76,100
-55,700
| -42% | -$3.59M | ﹤0.01% | 1511 |
|
|
2018
Q4 | $7.13M | Sell |
131,800
-17,700
| -12% | -$903K | 0.01% | 1355 |
|
|
2018
Q3 | $7.71M | Buy |
149,500
+25,900
| +21% | +$1.22M | 0.01% | 1445 |
|
|
2018
Q2 | $5.15M | Buy |
123,600
+6,000
| +5% | +$266K | ﹤0.01% | 1703 |
|
|
2018
Q1 | $5.18M | Sell |
117,600
-116,300
| -50% | -$5.91M | ﹤0.01% | 1614 |
|
|
2017
Q4 | $11.8M | Buy |
233,900
+43,900
| +23% | +$2.41M | 0.01% | 1099 |
|
|
2017
Q3 | $9.63M | Buy |
190,000
+9,200
| +5% | +$482K | 0.01% | 1080 |
|
|
2017
Q2 | $9.2M | Sell |
180,800
-21,900
| -11% | -$1.02M | 0.01% | 1025 |
|
|
2017
Q1 | $8.15M | Buy |
202,700
+45,200
| +29% | +$2.03M | 0.01% | 1012 |
|
|
2016
Q4 | $7.53M | Sell |
157,500
-85,400
| -35% | -$3.38M | 0.01% | 1105 |
|
|
2016
Q3 | $8.9M | Buy |
242,900
+201,700
| +490% | +$6.31M | 0.01% | 932 |
|
|
2016
Q2 | $960K | Sell |
41,200
-10,400
| -20% | -$335K | ﹤0.01% | 2649 |
|
|
2016
Q1 | $2.06M | Buy |
51,600
+11,400
| +28% | +$463K | ﹤0.01% | 1898 |
|
|
2015
Q4 | $2.45M | Sell |
40,200
-29,500
| -42% | -$1.59M | ﹤0.01% | 1859 |
|
|
2015
Q3 | $2.79M | Sell |
69,700
-25,200
| -27% | -$1.3M | ﹤0.01% | 1836 |
|
|
2015
Q2 | $5.41M | Buy |
94,900
+21,600
| +29% | +$1.37M | 0.01% | 1434 |
|
|
2015
Q1 | $4.62M | Sell |
73,300
-30,700
| -30% | -$2.08M | 0.01% | 1628 |
|
|
2014
Q4 | $6.34M | Buy |
104,000
+27,500
| +36% | +$1.36M | 0.01% | 1501 |
|
|
2014
Q3 | $2.91M | Sell |
76,500
-55,300
| -42% | -$1.96M | ﹤0.01% | 2316 |
|
|
2014
Q2 | $4.48M | Sell |
131,800
-146,200
| -53% | -$4.6M | ﹤0.01% | 1842 |
|
|
2014
Q1 | $12M | Buy |
278,000
+237,300
| +583% | +$11.5M | 0.01% | 1016 |
|
|
2013
Q4 | $1.59M | Buy |
40,700
+9,300
| +30% | +$331K | ﹤0.01% | 2914 |
|
|
2013
Q3 | $1.16M | Sell |
31,400
-224,700
| -88% | -$6.71M | ﹤0.01% | 3188 |
|
|
2013
Q2 | $6.88M | Buy |
+256,100
| New | +$5.45M | 0.01% | 1362 |
|
Other funds holding IONS
VPM
VCM
Barclays's IONS Position: Q1 2026 in Review
Barclays reduced its Ionis Pharmaceuticals (IONS) stake by 66% in Q1 2026, selling an estimated $43.6M and leaving 289,874 shares worth $21.8M. The position accounts for 0.01% of the portfolio, ranked #1059.
Barclays first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $66.7M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Barclays held 289,874 shares of Ionis Pharmaceuticals worth $21.8M as of Q1 2026.
- Barclays sold 552,997 Ionis Pharmaceuticals shares in Q1 2026, an estimated $43.6M.
- Ionis Pharmaceuticals made up 0.01% of Barclays's portfolio in Q1 2026, its #1059 holding.
- Barclays first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Ionis Pharmaceuticals position peaked at $66.7M in Q4 2025.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.